Invivyd, Inc. has announced the formation of the SPEAR Study Group, a clinical and translational study group focused on the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome. The group will conduct collaborative, multi-center translational clinical research to explore the biology and clinical disease associated with chronic exposure to the SARS-CoV-2 virus or mRNA vaccine-mediated spike protein. The study aims to evaluate the effects of broadly neutralizing anti-SARS-CoV-2 spike protein monoclonal antibody therapy, including Invivyd's next-generation candidates such as VYD2311, in individuals with Long COVID or Post-Vaccination Syndrome. The results of these trials will be presented in the future, as the research is in the planning and execution phase. The study group includes leading investigators such as Dr. Michael Peluso, Dr. Amy Proal, and Dr. David Putrino, who will work alongside Invivyd to design and implement the clinical trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.